Why this familiar blood marker may tell us more about metabolism, kidney function and inflammation than we once thought.

Uric acid is usually discussed in one context: gout. A blood test shows that uric acid is high, dietary purines are blamed, and the conversation quickly turns to red meat and alcohol.

Recent research into urate metabolism is revealing a much more complex picture. Uric acid sits at the meeting point of cellular energy metabolism, fructose processing, kidney function, intestinal clearance and innate immunity. And while persistently high uric acid can eventually lead to painful crystal deposition in the joints, the concentration in the blood is only one part of the story. So why does uric acid rise — and why does it cause inflammation in some people but not others?

First, what exactly is uric acid?

Uric acid is the final product of purine metabolism in humans. Purines are essential molecules found within DNA, RNA and cellular energy systems. They come partly from food, but they are also continually produced and recycled as our own cells turnover.

During purine breakdown we see: hypoxanthine → xanthine → uric acid. The final steps are controlled by the enzyme xanthine oxidase. This means uric acid itself is not abnormal. It is produced every day as part of normal human metabolism. In its soluble form, urate also contributes to antioxidant activity within the bloodstream. The problem develops when production and elimination fall out of balance.

High uric acid is often a clearance problem

The old explanation for gout focused heavily on eating too many purine-rich foods. Diet certainly plays a big role, but modern research places much greater emphasis on how the body handles urate after it has been produced.

The kidneys are responsible for most urate elimination. Rather than simply filtering uric acid into the urine, the kidney continuously filters, reabsorbs and secretes urate through specialised transport proteins. Among the most important are: URAT1, GLUT9 and ABCG2. Changes in these transporters — whether through genetics, kidney disease, medicines or metabolic dysfunction — can significantly alter serum urate. This helps explain why two people eating similar diets can have very different uric acid levels.

The intestine is part of the uric-acid story too

For years, uric-acid management was considered predominantly a kidney problem. We now know that approximately one-third of urate elimination occurs outside the kidneys, with the intestine representing the major extra-renal route.

The transporter ABCG2 helps move urate from the circulation into the intestinal lumen. From there, the intestinal microbiome may participate in its further metabolism. Recent research suggests that some gut bacteria may influence urate handling directly, while microbial metabolites may also alter expression of intestinal transporters such as ABCG2.

This does not yet mean that dysbiosis can be diagnosed as a cause of gout or that probiotics can be prescribed as urate-lowering therapy. But the gut–urate relationship is becoming an increasingly interesting area of research.

Then there is fructose

One of the most interesting developments in uric-acid research has been the connection with fructose metabolism. Fructose is metabolised differently from glucose.

When large amounts of fructose are rapidly processed in the liver, fructokinase uses ATP to convert fructose into fructose-1-phosphate. With a high fructose load, this process can transiently deplete cellular ATP. The resulting pathway looks like this:

Fructose → rapid ATP consumption → AMP breakdown → IMP → hypoxanthine → xanthine → uric acid

In other words, fructose can stimulate uric-acid production without providing dietary purines at all. This is one reason why sugar-sweetened drinks and high intakes of added sugars deserve particular attention when looking at elevated uric acid.

It also helps explain why hyperuricaemia frequently travels alongside insulin resistance, central obesity, fatty liver, raised triglycerides and metabolic syndrome.

Uric acid begins to look less like an isolated “gout marker” and more like part of a wider metabolic picture.

Alcohol affects more than dietary purines

Alcohol can also influence uric acid through several pathways. Ethanol metabolism alters hepatic energy metabolism and can increase lactate production, while renal urate excretion may also be reduced.

Beer adds another factor because it can provide both alcohol and purine-containing compounds derived from yeast.

So the relationship between alcohol and gout cannot be explained simply by saying that alcoholic drinks “contain purines”. The metabolic effect matters too.

Why doesn't everyone with high uric acid develop gout?

This is one of the most important questions. Many people have asymptomatic hyperuricaemia for years and never experience a gout attack. Elevated urate is therefore not the same thing as gout.

Gout develops when monosodium urate begins to crystallise within tissues. The approximate saturation point of urate in physiological conditions is around 6.8 mg/dL, or approximately 404 µmol/L, although crystal formation is also influenced by the local tissue environment.

Peripheral joints are particularly susceptible partly because lower temperatures favour crystallisation. But even the presence of crystals does not necessarily produce an immediate inflammatory attack. And this is where immunology becomes fascinating.

A gout attack is an immune reaction

The intense inflammation of gout is not simply caused by sharp crystals mechanically damaging the joint. The immune system recognises monosodium urate crystals as a danger signal.

Macrophages and other innate immune cells take up the crystals, producing intracellular stress signals that activate a molecular complex called the NLRP3 inflammasome.

Activation of NLRP3 leads to production of the inflammatory cytokine interleukin-1 beta — IL-1β.

IL-1β then drives the recruitment of large numbers of neutrophils into the joint. The inflammatory sequence can be simplified as:

Monosodium urate crystals → macrophage activation → NLRP3 inflammasome → IL-1β → neutrophil recruitment → acute inflammation

The result is the characteristic sudden onset of heat, redness, swelling and severe pain. Interestingly, newer work in immunometabolism suggests that crystal load alone does not fully explain why attacks occur. The metabolic state of macrophages and neutrophils, previous immune activation and the local joint environment may all influence whether deposited crystals remain relatively quiet or trigger a full inflammatory flare.

The inflammation can also switch itself off

Gout has another unusual feature. An untreated attack can eventually resolve even though urate crystals may still remain within the joint. Research suggests that neutrophils, macrophages, regulatory immune cells and specialised pro-resolving pathways participate in actively switching off the inflammatory response.

This means gout is not simply a story of inflammation being turned on. It is also a story of whether the immune system can successfully turn that inflammation off. That distinction may become increasingly important as researchers explore new therapeutic strategies.

Does an over-reactive immune response mean autoimmunity?

This is an important distinction. Gout itself is considered primarily an autoinflammatory disease, meaning that the inflammatory response is driven largely by the innate immune system — particularly macrophages, neutrophils and inflammatory signalling pathways such as NLRP3 and IL-1β — rather than by the autoantibodies or autoreactive T cells that characterise classic autoimmune diseases.

However, innate and adaptive immunity do not operate as completely separate  systems. Dysregulation of innate immunity can influence adaptive immune responses, and many inflammatory diseases sit somewhere along a continuum between predominantly autoinflammatory and predominantly autoimmune mechanisms.

More recent research also suggests that repeated exposure to urate crystals may leave innate immune cells in a more responsive or “trained” state even between attacks, although the clinical implications of this are still being investigated.

For this reason, an unusually strong or persistent inflammatory picture should not automatically be labelled as autoimmunity, but it may justify looking more carefully for a coexisting autoimmune or inflammatory disorder when the clinical pattern suggests one — for example, persistent joint swelling between gout attacks, symmetrical small-joint inflammation, prolonged morning stiffness, psoriasis or dactylitis, inflammatory back pain, uveitis, Raynaud phenomenon, sicca symptoms, unexplained rashes or other systemic features.

In other words, an over-reactive innate immune response does not prove autoimmunity — but it may be one clue within a broader picture of immune dysregulation.

Crystals are not the same as tophi

Monosodium urate crystals may accumulate within joints and surrounding tissues. A tophus, however, is not simply an individual crystal.

Tophi are organised deposits containing large quantities of urate crystals surrounded by inflammatory and connective-tissue responses. Over time, persistent crystal deposition and repeated inflammation can contribute to:

• cartilage damage
• bone erosions
• chronic synovitis
• restricted mobility
• joint deformity

What does diet really do?

Diet matters, but probably not in the simplistic way it is often presented. A very restrictive “low-purine diet” is not supported as a universal solution. Current NICE guidance notes that evidence is insufficient to recommend one specific diet that reliably prevents gout flares or lowers serum urate, and instead recommends a healthy balanced diet alongside management of excess weight and excessive alcohol consumption.

From a metabolic perspective, several areas deserve particular attention:

• excessive sugar-sweetened beverages and added fructose
• excessive alcohol
• obesity and insulin resistance
• dehydration
• rapid weight loss and prolonged fasting
• kidney function
• medicines that alter renal urate handling

Purine-rich foods remain relevant, but they form only one part of a much larger physiological picture.

What about treatment?

For established gout, the aim is not simply to stop an acute attack. Long-term treatment seeks to reduce serum urate sufficiently for existing crystals eventually to dissolve and further deposition to stop.

NICE currently recommends a treat-to-target strategy, generally aiming for serum urate below 360 µmol/L (6 mg/dL), with a lower target below 300 µmol/L (5 mg/dL) considered in more severe disease such as tophaceous or chronic gout.

Medicines such as allopurinol and febuxostat reduce uric-acid production by inhibiting xanthine oxidase. Other therapeutic approaches can alter urate excretion.

But research is increasingly opening additional questions:

• Could intestinal urate transport be manipulated?
• Could the microbiome influence meaningful urate clearance?
• Could inflammatory activation through NLRP3 be moderated independently of serum uric acid?
• And could metabolic interventions aimed at fructose handling and insulin resistance reduce the physiological drive towards hyperuricaemia?
  

Key Takeaways

• Uric acid is a normal product of human metabolism, not inherently a toxin.
• Hyperuricaemia develops when urate production exceeds the body's ability to eliminate it.
• The kidneys remain central, but intestinal elimination and ABCG2-mediated transport are increasingly recognised as important contributors.
• High fructose exposure can increase uric-acid production through ATP depletion and accelerated purine breakdown.
• Elevated uric acid is frequently associated with wider metabolic dysfunction, including insulin resistance, obesity and kidney disease.
• Gout occurs when monosodium urate crystals form and provoke an innate immune response involving NLRP3, IL-1β and neutrophils.
• And perhaps most importantly: high uric acid, urate crystals and an acute gout attack are related — but they are not the same biological event.

Understanding that distinction gives us a much clearer picture of where prevention and treatment may eventually intervene.

Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice, diagnosis or treatment.

Joint pain, swelling and redness can have causes other than gout, including joint infection, and require appropriate clinical assessment. An elevated serum urate result alone does not establish a diagnosis of gout.

People with gout, kidney disease, cardiovascular disease or other medical conditions, and those taking prescribed medicines, should discuss dietary changes, supplements or herbal medicines with an appropriately qualified healthcare professional. Prescribed urate-lowering or anti-inflammatory medicines should not be started, stopped or altered without medical guidance.

Herbal and nutritional approaches discussed in Wildberry Clinic's Research in Focus series are considered within an integrative clinical framework and are not substitutes for appropriate medical investigation or treatment.

References

1. Chung S, Kim GH. Urate Transporters in the Kidney: What Clinicians Need to Know. Electrolyte & Blood Pressure. 2021;19(1):1–9. doi:10.5049/EBP.2021.19.1.1.

2. Kim SH, Shin J, Son HE, Kang DH. Role of urate transporters in the kidneys and intestine in uric acid homeostasis. Kidney Research and Clinical Practice. 2026;45(3):296–313. doi:10.23876/j.krcp.24.321.

3. Jamnik J, Rehman S, Blanco Mejia S, de Souza RJ, Khan TA, Leiter LA, Wolever TMS, Kendall CWC, Jenkins DJA, Sievenpiper JL. Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies. BMJ Open. 2016;6(10). doi:10.1136/bmjopen-2016-013191.

4. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review. Nutrients. 2017;9(4):395. doi:10.3390/nu9040395.

5. National Institute for Health and Care Excellence (NICE). Gout: diagnosis and management. NICE Guideline NG219. London: NICE; 2022. Published 9 June 2022.

6. Poulsen R, Dalbeth N. Gout and NLRP3 Inflammasome Biology. Arthritis & Rheumatology. 2025;77(10):1317–1326. doi:10.1002/art.43215.

7. Galozzi P, Bindoli S, Doria A, Oliviero F, Sfriso P. Autoinflammatory Features in Gouty Arthritis. Journal of Clinical Medicine. 2021;10(9):1880. doi:10.3390/jcm10091880.

8. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annual Review of Immunology. 2009;27:621–668. doi:10.1146/annurev.immunol.25.022106.141627.

9. Wang K, Li J, Li J, Zeng F, Li S, Chen P, Xiong H. Spatiotemporal immune gradients in gout: immune response-driven activation of the NLRP3–IL-1β axis and its transition to trained immunity. Frontiers in Immunology. 2026;17:1776479. doi:10.3389/fimmu.2026.1776479.

Coming Next

Can medicinal plants influence uric-acid metabolism?

We will look at the research on botanical compounds affecting xanthine oxidase, urate transporters, the NLRP3 inflammasome and intestinal urate clearance — and separate plausible mechanisms from traditional claims.